Repeated vobra duo doses ameliorated this outcome, reverting rhabdomyosarcorma to rhabdomyoma tumor, by increasing Desmin and Myogenin/Myf-4 differentiation markers expression, and reducing both Ki-67 and CD133. In conclusion, the in vitro and in vivo anti-tumor effects towards pSC highlight the need to extend the investigation to patient-derived preclinical models, to pave the way for clinical translation.

12 days ago

Preclinical • Journal

CD276 (CD276 Molecule) • CASP3 (Caspase 3) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1)

vobramitamab duocarmazine (MGC018)

13d

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=84, Recruiting, GlaxoSmithKline | Phase classification: P1/2 --> P1 | Not yet recruiting --> Recruiting

13 days ago

Enrollment open • Phase classification

Avastin (bevacizumab) • 5-fluorouracil • Xtandi (enzalutamide) • leucovorin calcium • risvutatug rezetecan (GSK5764227)

15d

GenSci143 in Participants With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=180, Recruiting, Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting

15 days ago

Enrollment open • First-in-human

28d

SKB500 Combinations in Patients With Small Cell Lung Cancer (clinicaltrials.gov)

P2, N=80, Not yet recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

28 days ago

New P2 trial

carboplatin • etoposide IV

A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101) (clinicaltrials.gov)

P1, N=590, Recruiting, GlaxoSmithKline | N=316 --> 590

1 month ago

Enrollment change • Pan tumor

Keytruda (pembrolizumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • Imfinzi (durvalumab) • risvutatug rezetecan (GSK5764227)

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov)

P1/2, N=72, Not yet recruiting, GlaxoSmithKline

1 month ago

New P1/2 trial

Avastin (bevacizumab) • 5-fluorouracil • Xtandi (enzalutamide) • leucovorin calcium • risvutatug rezetecan (GSK5764227)

A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors (clinicaltrials.gov)

P1, N=168, Completed, AbbVie | Active, not recruiting --> Completed | Trial completion date: Jun 2025 --> Sep 2025 | Trial primary completion date: Jun 2025 --> Sep 2025

1 month ago

Trial completion • Trial completion date • Trial primary completion date • First-in-human

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

PD-L1 expression • HER-2 positive • EGFR mutation • HR positive • BRAF mutation • HER-2 negative • ALK mutation • ROS1 positive • HR positive + HER-2 negative

paclitaxel • docetaxel • mirzotamab clezutoclax (ABBV-155)

2ms

Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer (clinicaltrials.gov)

P1, N=63, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting

2 months ago

Enrollment open

HRS-5041 • risvutatug rezetecan (GSK5764227)

2ms

A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma. (clinicaltrials.gov)

P1/2, N=202, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd.

2 months ago

New P1/2 trial